[{"indications": "Indications\u00a0see notes above; prostate\r\ncancer (%s\n(From 8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists: British National Formulary)\n8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists)", "name": "CYPROTERONE ACETATE - CYPROTERONE ACETATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.4 Sex hormones", "6.4.2 Male sex hormones and antagonists", "Anti-androgens", "Cyproterone acetate", "CYPROTERONE ACETATE"], "cautions": "Cautions\u00a0ineffective for male hypersexuality in\r\nchronic alcoholism (relevance to prostate cancer\r\nnot known); blood counts initially and\r\nthroughout treatment; monitor hepatic function\r\nregularly (liver function tests should\r\nbe performed before treatment, see also under Side-effects\r\nbelow); monitor adrenocortical function regularly; diabetes mellitus (see also Contra-indications)Driving\u00a0Fatigue and lassitude may\r\nimpair performance of skilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0fatigue and lassitude, breathlessness, weight\r\nchanges, reduced sebum production (may clear acne), changes in hair\r\npattern, gynaecomastia (rarely leading to galactorrhoea and benign\r\nbreast nodules); rarely hypersensitivity reactions, rash and osteoporosis;\r\ninhibition of spermatogenesis (see notes above); hepatotoxicity reported\r\n(including jaundice, hepatitis and hepatic failure (fatalities reported\r\nat dosages of 100\u00a0mg and above, usually in men treated for advanced\r\nprostate cancer), \n(From CYPROTERONE ACETATE: British National Formulary)\nSide-effects\u00a0see section 6.4.2Hepatotoxicity\u00a0Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported (fatalities reported at dosages of 100\u00a0mg and above, usually in men treated for advanced prostate cancer). Liver function tests should be performed before and regularly during treatment and whenever symptoms suggestive of hepatotoxicity occur\u2014if confirmed cyproterone should normally be withdrawn unless the hepatotoxicity can be explained by another cause such as metastatic disease (in which case cyproterone should be continued only if the perceived benefit exceeds the risk) for details and warnings)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/86559.htm", "doses": ["adult over 18 years, male\r\nhypersexuality, 50\u00a0mg twice daily after food"]}, {"indications": "Indications\u00a0prostate cancer, see under\r\nDose and also notes above; other indications, see section 6.4.2", "name": "CYPROTERONE ACETATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists", "Anti-androgens"], "cautions": "Cautions\u00a0in prostate cancer, blood counts initially and throughout\r\ntreatment; monitor hepatic function (liver function tests should be performed\r\nbefore treatment, see also under Side-effects below); monitor adrenocortical function regularly; risk of recurrence of thromboembolic disease; diabetes mellitus, sickle-cell anaemia, severe depression (in other indications\r\nsome of these are contra-indicated, see section 6.4.2) Driving\u00a0Fatigue and lassitude may\r\nimpair performance of skilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0see section 6.4.2Hepatotoxicity\u00a0Direct hepatic toxicity including\r\njaundice, hepatitis and hepatic failure have been reported (fatalities\r\nreported at dosages of 100\u00a0mg and above, usually in men treated for\r\nadvanced prostate cancer). Liver function tests should\r\nbe performed before and regularly during treatment and whenever symptoms\r\nsuggestive of hepatotoxicity occur\u2014if confirmed cyproterone\r\nshould normally be withdrawn unless the hepatotoxicity can be explained\r\nby another cause such as metastatic disease (in which case cyproterone\r\nshould be continued only if the perceived benefit exceeds the risk)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4826.htm", "doses": ["Prevention of flare with initial gonadorelin analogue therapy, 200\u00a0mg daily in 2\u20133 divided doses for 5\u20137 days\r\nbefore initiation of gonadorelin analogue, followed by 200\u00a0mg daily\r\nin 2\u20133 divided doses for 3\u20134 weeks after initiation of gonadorelin\r\nanalogue; max. 300\u00a0mg daily", "Long-term palliative therapy where gonadorelin analogues or orchidectomy contra-indicated, not tolerated, or where\r\noral therapy preferred, 200\u2013300\u00a0mg daily in 2\u20133 divided doses", "Hot flushes with gonadorelin analogue therapy\r\nor after orchidectomy, initially 50\u00a0mg daily, adjusted according to\r\nresponse to 50\u2013150\u00a0mg daily in 1\u20133 divided doses"]}, {"indications": "Indications\u00a0prostate cancer, see under\r\nDose and also notes above; other indications, see section 6.4.2", "name": "CYPROTERONE ACETATE - GONADORELIN ANALOGUES AND GONADOTROPHIN-RELEASING HORMONE ANTAGONISTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.3 Sex hormones and hormone antagonists in malignant disease", "8.3.4 Hormone antagonists", "8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists", "Anti-androgens"], "cautions": "Cautions\u00a0in prostate cancer, blood counts initially and throughout\r\ntreatment; monitor hepatic function (liver function tests should be performed\r\nbefore treatment, see also under Side-effects below); monitor adrenocortical function regularly; risk of recurrence of thromboembolic disease; diabetes mellitus, sickle-cell anaemia, severe depression (in other indications\r\nsome of these are contra-indicated, see section 6.4.2) Driving\u00a0Fatigue and lassitude may\r\nimpair performance of skilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0see section 6.4.2Hepatotoxicity\u00a0Direct hepatic toxicity including\r\njaundice, hepatitis and hepatic failure have been reported (fatalities\r\nreported at dosages of 100\u00a0mg and above, usually in men treated for\r\nadvanced prostate cancer). Liver function tests should\r\nbe performed before and regularly during treatment and whenever symptoms\r\nsuggestive of hepatotoxicity occur\u2014if confirmed cyproterone\r\nshould normally be withdrawn unless the hepatotoxicity can be explained\r\nby another cause such as metastatic disease (in which case cyproterone\r\nshould be continued only if the perceived benefit exceeds the risk)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4826.htm", "doses": ["Prevention of flare with initial gonadorelin analogue therapy, 200\u00a0mg daily in 2\u20133 divided doses for 5\u20137 days\r\nbefore initiation of gonadorelin analogue, followed by 200\u00a0mg daily\r\nin 2\u20133 divided doses for 3\u20134 weeks after initiation of gonadorelin\r\nanalogue; max. 300\u00a0mg daily", "Long-term palliative therapy where gonadorelin analogues or orchidectomy contra-indicated, not tolerated, or where\r\noral therapy preferred, 200\u2013300\u00a0mg daily in 2\u20133 divided doses", "Hot flushes with gonadorelin analogue therapy\r\nor after orchidectomy, initially 50\u00a0mg daily, adjusted according to\r\nresponse to 50\u2013150\u00a0mg daily in 1\u20133 divided doses"]}]